Month: January 2026

PRESS RELEASE                                         Share Buyback Transaction Details January 22 – January 28, 2026 Alphen aan den Rijn – January 29, 2026 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 162,847 of its own ordinary shares in the period from January 22, 2026, up to and including January 28, 2026, for €13.5 million and at an average share price of €82.69. These repurchases are part of the share buyback program announced on November 5, 2025, under which we intend to repurchase shares for up to € 200 million from November 6, 2025, up to February 23, 2026. The cumulative amounts repurchased in the year to date are as follows: Share Buyback 2026Period Cumulative shares repurchased in period Total consideration(€ million) Average...

Frankfurt, 29th of January 2026 – Swedish regulated crypto asset manager Virtune today announced the listing of the Virtune Sui ETP on Deutsche Börse Xetra, becoming the first Sui ETP available on Xetra. Virtune is a Swedish digital asset manager and issuer of physically backed crypto exchange-traded products (ETPs). Since its launch in 2023, Virtune has earned the trust of over 152,000 investors and today manages around USD 340 million in assets under management (AUM), reinforcing its position as one of Europe’s leading issuers of regulated crypto ETPs. Virtune is now expanding its German offering with the listing of the Virtune Sui ETP. The product is now also available to Swedish investors through brokers and banks such as Avanza and Montrose. This listing underscores Virtune’s commitment to providing European investors with secure,...

IBM, Accenture and Capgemini among those recognized for their commitment to excellence GRAND-LANCY, Switzerland, Jan. 29, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced the winners of its annual Partner awards, which recognize the excellence of Temenos Partners in driving innovation and customer success. William Moroney, Chief Revenue Officer, Temenos, commented: “Our Partners play a key role in helping Temenos transform banking and deepen our presence in key markets and larger banks, accelerating innovation and delivering better outcomes for our customers at scale. Congratulations to the winners of the Temenos Partner Awards, and thank you to all our Partners for their trust and collaboration; together, we are leading banking forward.”  Sales Partner of the Year – Corebanx Based...

REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea® 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area, United Kingdom and Japan. In combination with the previously announced agreement which granted a Q4 2026 license entry date for the U.S., pending regulatory approval, Alvotech now has worldwide rights to manufacture and supply its global commercial partners with the aflibercept biosimilar. The settlement agreement allows Alvotech and its commercial...

REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea® 2mg (aflibercept 40 mg/mL solution), which is approved for marketing in the European Economic Area, United Kingdom and Japan. In combination with the previously announced agreement which granted a Q4 2026 license entry date for the U.S., pending regulatory approval, Alvotech now has worldwide rights to manufacture and supply its global commercial partners with the aflibercept biosimilar. The settlement agreement allows Alvotech and its commercial partners to...

Sampo plc, press release, 29 January 2026 at 10:00 am EET Sampo Group’s results for 2025 will be published on 5 February 2026 Sampo Group will publish the Financial Statement Release for 2025 on 5 February around 8:30 am Finnish time (6:30 am UK time). The report, the investor presentation, and a video review with Group CEO Morten Thorsrud will be available at www.sampo.com/result. Conference call 5 February at 10:30 am Finnish time (8:30 am UK time) To ask questions, please join the teleconference by registering using the following link: https://events.inderes.com/sampo/q4-2025-y6emjr90zj/dial-in. Upon registration, you will receive phone numbers as well as a conference ID and user ID to access the conference. If you wish to ask a question, please dial #5 on your telephone keypad to enter the queue. Group CEO Morten Thorsrud, Group...

The new ETP provides liquid access to JitoSOL, combining full Solana price exposure with a dual-source staking yield Zurich, 29 January 2026 — 21shares, one of the world’s largest issuers of cryptocurrency exchange-traded products (ETPs), today announced the launch of the 21shares Jito Staked SOL ETP (JSOL), providing investors with liquid, exchange-traded access to JitoSOL, the leading liquid staking asset within the Solana ecosystem. JSOL enables investors to access JitoSOL through their existing bank or broker, combining Solana market exposure with the enhanced rewards of liquid staking in a transparent, exchange-traded format.Product name: 21shares Jito Staked SOL ETP ISIN: CH1521714696 Ticker & currencies: JSOL NA (USD), JSOL FP (EUR) Exchanges: Euronext Amsterdam and Paris Inception date: 29 January 2026 Issuer: 21Shares AG Total...

BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) — JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). The journal concluded that soficitinib demonstrated a favorable safety profile and encouraging efficacy, supporting further development for AD. This is a double-blind, placebo-controlled, phase 2 randomized clinical trial aiming to evaluate the safety and efficacy of soficitinib for moderate to severe AD. 75 participants were randomized 1:1:1 to receive soficitinib at 80 mg or 120 mg, or placebo orally once daily. The primary endpoint was safety and efficacy. The key efficacy endpoint was the percentage change from baseline in Eczema Area and Severity Index (EASI) at week 4. Other endpoints included percentages of patients...